Skip to main content
AMLX logo

AMLX · Amylyx Pharmaceuticals, Inc. · Analyst Estimates

Track AMLX — free
$28.04 +0.26 (+0.94%) At close · Oct 6
Market Cap
$3.33B
Shares
111.42M
Volume · Oct 6 1.28M Avg daily vol (3M) 2.3M

Analyst Estimates

Compare analyst forecasts for Amylyx Pharmaceuticals, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-09-18 17:31 UTC · Publication dates shown per estimate · 16 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-1.6
-1.49716
-1.36728
—
-1.38466
-1.38466
-1.47121
-1.38466
— — — —
EPS
analysts
Publication date not stated
— — —
8
— — — —
4
2
2
0
Revenue
USD
Publication date not stated
0
0
0
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
11
— — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-1.69753
-1.15469
0.7
—
-1.266
-1.266
-1.37617
-1.266
— — — —
EPS
analysts
Publication date not stated
— — —
8
— — — —
3
2
3
3
Revenue
USD
Publication date not stated
5880860
28228400
54000000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
10
— — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-0.42
-0.37499
-0.33
—
-0.3346
-0.3346
-0.36498
-0.3346
— — — —
EPS
analysts
Publication date not stated
— — —
8
— — — —
4
2
2
0
Revenue
USD
Publication date not stated
0
37820
416000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
11
— — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-0.41
-0.36638
-0.26107
—
-0.34166
-0.34166
-0.35684
-0.34166
— — — —
EPS
analysts
Publication date not stated
— — —
8
— — — —
3
2
4
0
Revenue
USD
Publication date not stated
-416000
-37820
0
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
11
— — — — — — — —
Key facts CIK 1658551 CUSIP 03237H101 13F (30d) 4 filings 4 filers Visit website Investor relations